CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi
Molecular Therapy · 2023-07 · 31 (7) · 1920-1937
DOI: 10.1016/j.ymthe.2023.03.024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2023-07. Verfasst von Louise Bendixen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Aarhus University, 8000 Aarhus C, Denmark. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing. Die Arbeit wurde bisher 149-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Danish Health Authority, Novo Nordisk Fonden, Agnes og Poul Friis Fond.
Abstract (Originalsprache)
The CRISPR-Cas system is commonly known for its ability to cleave DNA in a programmable manner, which has democratized gene editing and facilitated recent breakthroughs in gene therapy. However, newer iterations of the technology using nuclease-disabled Cas enzymes have spurred a variety of different types of genetic engineering platforms such as transcriptional modulation using the CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi) systems. This review introduces the creation of these programmable transcriptional modulators, various methods of delivery utilized for these systems, and recent technological developments. CRISPRa and CRISPRi have also been implemented in genetic screens for interrogating gene function and discovering genes involved in various biological pathways. We describe recent compelling examples of how these tools have become powerful means to unravel genetic networks and uncovering important information about devastating diseases. Finally, we provide an overview of preclinical studies in which transcriptional modulation has been used therapeutically, and we discuss potential future directions of these novel modalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedicine, Aarhus University, 8000 Aarhus C, Denmark.
- Department of Biomedicine, Aarhus University, 8000 Aarhus C, Denmark. Electronic address: bak@biomed.au.dk.
Förderung
- Danish Health Authority
- Novo Nordisk Fonden
- Agnes og Poul Friis Fond
- Danmarks Frie Forskningsfond
- European Research Council
- Independent Research Fund Denmark
- A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
- Riisfort Fonden
Zitieren
APA
Bendixen, L., Jensen, T. I., & Bak, R. O. (2023). CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi. Molecular Therapy, 31(7), 1920-1937. https://doi.org/10.1016/j.ymthe.2023.03.024
Vancouver
Bendixen L, Jensen TI, Bak RO. CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi. Molecular Therapy. 2023;31(7):1920-1937. doi:10.1016/j.ymthe.2023.03.024
BibTeX
@article{Bendixen2023,
author = {Bendixen, Louise and Jensen, Trine I and Bak, Rasmus O},
title = {CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi},
journal = {Molecular Therapy},
year = {2023},
volume = {31},
number = {7},
pages = {1920--1937},
doi = {10.1016/j.ymthe.2023.03.024}
}
EUVIMED